

# Jeff Szer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/853259/publications.pdf>

Version: 2024-02-01

366  
papers

15,630  
citations

23567

58  
h-index

20961

115  
g-index

372  
all docs

372  
docs citations

372  
times ranked

13494  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of donor age on adult unrelated donor haemopoietic cell transplant outcome: the Australian experience. <i>Internal Medicine Journal</i> , 2022, 52, 57-62.	0.8	0
2	One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. <i>Haematologica</i> , 2022, 107, 1045-1053.	3.5	87
3	Composite endpoint to evaluate complement inhibition therapy in patients with paroxysmal nocturnal hemoglobinuria. <i>European Journal of Haematology</i> , 2022, 108, 391-402.	2.2	4
4	The Journal in 2021. <i>Internal Medicine Journal</i> , 2022, 52, 5-6.	0.8	0
5	Lactate dehydrogenase versus haemoglobin: which one is the better marker in paroxysmal nocturnal haemoglobinuria?. <i>British Journal of Haematology</i> , 2022, 196, 264-265.	2.5	7
6	Worldwide Network for Blood and Marrow Transplantation Special Article on Key Elements in Quality and Accreditation in Hematopoietic Stem Cell Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 455-462.	1.2	2
7	Infective hyperammonaemic encephalopathy after allogeneic stem cell transplant. <i>Bone Marrow Transplantation</i> , 2022, , .	2.4	1
8	The Journal in 2020. <i>Internal Medicine Journal</i> , 2021, 51, 5-6.	0.8	0
9	Wine & Blood. An Unlikely Pairing By Shaun R.McCann. Moldova: Eliva Press; 2020. 104 pp. (Paperback). ISBN 978â€9975â€3417â€7â€6. <i>Internal Medicine Journal</i> , 2021, 51, 157-157.	0.8	0
10	Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. <i>New England Journal of Medicine</i> , 2021, 384, 1028-1037.	27.0	187
11	Worldwide Network for Blood and Marrow Transplantation (WBMT) Recommendations Regarding Essential Medications Required To Establish An Early Stage Hematopoietic Cell Transplantation Program. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 267.e1-267.e5.	1.2	6
12	Hematological manifestations and complications of Gaucher disease. <i>Expert Review of Hematology</i> , 2021, 14, 347-354.	2.2	14
13	Clinical ethics resources from the Royal Australasian College of Physicians. <i>Journal of Paediatrics and Child Health</i> , 2021, 57, 751-751.	0.8	0
14	<scp>COVID</scp>â€19 vaccination in haematology patients: an Australian and New Zealand consensus position statement. <i>Internal Medicine Journal</i> , 2021, 51, 763-768.	0.8	12
15	Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 921.e1-921.e10.	1.2	11
16	<scp>COVID</scp>â€19: looking backward. <i>Internal Medicine Journal</i> , 2021, 51, 1203-1204.	0.8	0
17	Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia. <i>Internal Medicine Journal</i> , 2021, 51, 1707-1712.	0.8	1
18	Immune thrombocytopenia following immunisation with Vaxzevria ChadOx1-S (AstraZeneca) vaccine, Victoria, Australia. <i>Vaccine</i> , 2021, 39, 7052-7057.	3.8	24

#	ARTICLE	IF	CITATIONS
19	Oromandibular parafunction in chronic graft-versus-host disease: novel association and treatment approach. <i>Internal Medicine Journal</i> , 2021, 51, 1950-1953.	0.8	3
20	We must grow the Australian Bone Marrow Donor Registry. <i>Internal Medicine Journal</i> , 2021, 51, 1771-1772.	0.8	1
21	Consensus guidelines for improving patients' understanding of invasive fungal disease and related risk prevention in the haematology/oncology setting, 2021. <i>Internal Medicine Journal</i> , 2021, 51, 220-233.	0.8	6
22	Special report: Summary of the first meeting of African Blood and Marrow Transplantation (AfBMT) group, Casablanca, Morocco, April 19-21, 2018 held under the auspices of the Worldwide Network for Blood and Marrow Transplantation (WBMT). <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2020, 13, 202-207.	0.9	15
23	Nivolumab induces dynamic alterations in CD8 T-cell function and TIM-3 expression when used to treat relapsed acute myeloid leukemia after allogeneic stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2020, 61, 185-188.	1.3	2
24	Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic stem cell transplantation program in countries with limited resources (Part II): Clinical, technical and socio-economic considerations. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2020, 13, 7-16.	0.9	17
25	Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic cell transplantation program (Part I): Minimum requirements and beyond. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2020, 13, 131-142.	0.9	14
26	Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries. <i>Bone Marrow Transplantation</i> , 2020, 55, 698-707.	2.4	4
27	Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 472-479.	2.0	21
28	Comparison of outcomes of HCT in blast phase of <i>BCR-ABL1</i> MPN with de novo AML and with AML following MDS. <i>Blood Advances</i> , 2020, 4, 4748-4757.	5.2	14
29	Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era: A Retrospective Analysis from the Australasian Bone Marrow Transplant Recipient Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2252-2261.	2.0	6
30	Impact of Gaucher disease on COVID-19. <i>Internal Medicine Journal</i> , 2020, 50, 894-895.	0.8	17
31	Treatable lysosomal storage diseases in the advent of disease-specific therapy. <i>Internal Medicine Journal</i> , 2020, 50, 5-27.	0.8	11
32	Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2181-2189.	2.0	51
33	Patient reported outcome measures in a large cohort of patients with type 1 Gaucher disease. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 284.	2.7	13
34	The Global State of Hematopoietic Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation Database and the Global Burden of Disease Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2372-2377.	2.0	19
35	Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance. <i>Medical Journal of Australia</i> , 2020, 212, 481-489.	1.7	107
36	Utility of clinical comprehensive genomic characterization for diagnostic categorization in patients presenting with hypocellular bone marrow failure syndromes. <i>Haematologica</i> , 2020, 106, 64-73.	3.5	14

#	ARTICLE	IF	CITATIONS
37	Hematopoietic Stem Cell Transplant Recipients Surviving at Least 2 Years from Transplant Have Survival Rates Approaching Population Levels in the Modern Era of Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1711-1718.	2.0	9
38	The impact of COVID-19 on the provision of donor hematopoietic stem cell products worldwide: collateral damage. <i>Bone Marrow Transplantation</i> , 2020, 55, 2043-2044.	2.4	35
39	The Journal in 2019. <i>Internal Medicine Journal</i> , 2020, 50, 9-10.	0.8	0
40	A synonymous GATA2 variant underlying familial myeloid malignancy with striking intrafamilial phenotypic variability. <i>British Journal of Haematology</i> , 2020, 190, e297-e301.	2.5	14
41	Is there no place like home for an allogeneic stem cell transplant?. <i>Bone Marrow Transplantation</i> , 2020, 55, 855-856.	2.4	1
42	COVID-19: looking forward. <i>Internal Medicine Journal</i> , 2020, 50, 657-657.	0.8	3
43	Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. <i>New England Journal of Medicine</i> , 2020, 382, 1800-1810.	27.0	455
44	The definition of neuronopathic Gaucher disease. <i>Journal of Inherited Metabolic Disease</i> , 2020, 43, 1056-1059.	3.6	51
45	Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria. <i>Haematologica</i> , 2020, 106, 230-237.	3.5	77
46	Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies. <i>British Journal of Haematology</i> , 2020, 191, 476-485.	2.5	38
47	Pegcetacoplan Is Superior to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria Regardless of Prior Transfusion Requirement. <i>Blood</i> , 2020, 136, 32-33.	1.4	1
48	Results of the Pegasus Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria. <i>Blood</i> , 2020, 136, 35-37.	1.4	2
49	Pre-Transplant Marital Status and Hematopoietic Cell Transplantation Outcomes. <i>Current Oncology</i> , 2020, 27, 596-606.	2.2	2
50	Longitudinal Genomic Characterization Using Cell-Free DNA in Patients with Idiopathic Aplastic Anemia. <i>Blood</i> , 2020, 136, 5-6.	1.4	0
51	Biomarker Analysis in Patients (pts) with Steroid-Refractory Acute Graft-Vs-Host Disease (aGVHD) Treated with Ruxolitinib (RUX) or Best Available Therapy (BAT) in the Randomized, Phase 3 REACH2 Study. <i>Blood</i> , 2020, 136, 26-27.	1.4	1
52	Effect of Pegcetacoplan on Quality of Life in Patients with Paroxysmal Nocturnal Hemoglobinuria from the Pegasus Phase 3 Trial Comparing Pegcetacoplan to Eculizumab. <i>Blood</i> , 2020, 136, 10-12.	1.4	8
53	Efficacy and Safety of Ravulizumab in Older Patients Aged >65 Years with Paroxysmal Nocturnal Hemoglobinuria in the 301 and 302 Phase 3 Extension Studies. <i>Blood</i> , 2020, 136, 42-43.	1.4	0
54	Strategies to enhance the graft versus tumour effect after allogeneic haematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 175-189.	2.4	6

#	ARTICLE	IF	CITATIONS
55	Narrowing the gap for hematopoietic stem cell transplantation in the East-Mediterranean/African region: comparison with global HSCT indications and trends. <i>Bone Marrow Transplantation</i> , 2019, 54, 402-417.	2.4	31
56	Recombinant Zoster Vaccine Significantly Reduces the Impact on Quality of Life Caused by Herpes Zoster in Adult Autologous Hematopoietic Stem Cell Transplant Recipients: A Randomized Placebo-Controlled Trial (ZOE-HSCT). <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2474-2481.	2.0	30
57	Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study. <i>Lancet Haematology</i> , 2019, 6, e122-e131.	4.6	20
58	The Concentration of Total Nucleated Cells in Harvested Bone Marrow for Transplantation Has Decreased over Time. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1325-1330.	2.0	13
59	Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Cell Transplantation Program, Part I: Minimum Requirements and Beyond. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2322-2329.	2.0	21
60	Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Stem Cell Transplantation Program in Countries with Limited Resources, Part II: Clinical, Technical, and Socioeconomic Considerations. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2330-2337.	2.0	22
61	The Journal in 2018. <i>Internal Medicine Journal</i> , 2019, 49, 7-8.	0.8	2
62	Worldwide Network for Blood & Marrow Transplantation (WBMT) special article, challenges facing emerging alternate donor registries. <i>Bone Marrow Transplantation</i> , 2019, 54, 1179-1188.	2.4	51
63	GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. <i>Blood Advances</i> , 2019, 3, 1441-1449.	5.2	12
64	Presenting signs and patient co-variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED) Delphi initiative. <i>Internal Medicine Journal</i> , 2019, 49, 578-591.	0.8	39
65	Revisiting acquired aplastic anaemia: current concepts in diagnosis and management. <i>Internal Medicine Journal</i> , 2019, 49, 152-159.	0.8	15
66	Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. <i>Blood</i> , 2019, 133, 540-549.	1.4	239
67	Current use of biosimilar G-CSF for haematopoietic stem cell mobilisation. <i>Bone Marrow Transplantation</i> , 2019, 54, 858-866.	2.4	15
68	One and Half Million Hematopoietic Stem Cell Transplants (HSCT). Dissemination, Trends and Potential to Improve Activity By Telemedicine from the Worldwide Network for Blood and Marrow Transplantation (WBMT). <i>Blood</i> , 2019, 134, 2035-2035.	1.4	36
69	The Global State of Hematopoietic Stem Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation (WBMT) Database and the Global Burden of Disease Study. <i>Blood</i> , 2019, 134, 412-412.	1.4	0
70	Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. <i>Lancet Haematology</i> , 2018, 5, e117-e126.	4.6	81
71	Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2018, 53, 535-555.	2.4	75
72	Prognostic markers in core-binding factor AML and improved survival with multiple consolidation cycles of intermediate-high-dose cytarabine. <i>European Journal of Haematology</i> , 2018, 101, 174-184.	2.2	9

#	ARTICLE	IF	CITATIONS
73	The Journal in 2017. Internal Medicine Journal, 2018, 48, 7-8.	0.8	1
74	Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease. Blood Cells, Molecules, and Diseases, 2018, 68, 203-208.	1.4	82
75	Combined beta-glucosylceramide and ambroxol hydrochloride in patients with Gaucher related Parkinson disease: From clinical observations to drug development. Blood Cells, Molecules, and Diseases, 2018, 68, 117-120.	1.4	14
76	Classifying the additional morbidities of Gaucher disease. Blood Cells, Molecules, and Diseases, 2018, 68, 209-210.	1.4	2
77	Design of a framework for the deployment of collaborative independent rare disease-centric registries: Gaucher disease registry model. Blood Cells, Molecules, and Diseases, 2018, 68, 232-238.	1.4	17
78	Intraobserver and interobserver variability of the bone marrow burden (BMB) score for the assessment of disease severity in Gaucher disease. Possible impact of reporting experience. Blood Cells, Molecules, and Diseases, 2018, 68, 121-125.	1.4	14
79	Acute myeloid leukaemia relapsing after allogeneic haemopoietic stem cell transplantation: prognostic factors and impact of initial therapy of relapse. Internal Medicine Journal, 2018, 48, 276-285.	0.8	13
80	Assessment of Impact of HLA Type on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia. Biology of Blood and Marrow Transplantation, 2018, 24, 581-586.	2.0	5
81	Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34+ Yields Are Less. Biology of Blood and Marrow Transplantation, 2018, 24, 175-184.	2.0	7
82	Activity and Capacity Profile of Transplant Physicians and Centers in Australia and New Zealand. Biology of Blood and Marrow Transplantation, 2018, 24, 169-174.	2.0	4
83	Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 228-241.	2.0	43
84	Should eliglustat be first line therapy for patients with type 1 Gaucher disease? Definitions of safety and efficacy. Blood Cells, Molecules, and Diseases, 2018, 68, 14-16.	1.4	12
85	Preface to the special issue on Gaucher disease 2017. Blood Cells, Molecules, and Diseases, 2018, 68, 1-2.	1.4	0
86	Recent advances and future challenges in Gaucher disease. Blood Cells, Molecules, and Diseases, 2018, 68, 9-13.	1.4	3
87	2482. Impact of a Recombinant Zoster Vaccine on Quality of Life: Data from a Randomized, Placebo-Controlled, Phase 3 Trial in Adult Hematopoietic Stem Cell Transplant Recipients. Open Forum Infectious Diseases, 2018, 5, S744-S744.	0.9	0
88	Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies. Blood Advances, 2018, 2, 2176-2185.	5.2	65
89	How we manage Gaucher Disease in the era of choices. British Journal of Haematology, 2018, 182, 467-480.	2.5	75
90	Activating killer cell immunoglobulin-like receptor haplotype influences clinical outcome following HLA-matched sibling haematopoietic stem cell transplantation. Hla, 2018, 92, 74-82.	0.6	11



#	ARTICLE	IF	CITATIONS
91	Rapid intravenous infusion of velaglucerase $\alpha$ in adults with type 1 Gaucher disease. American Journal of Hematology, 2018, 93, E246-E248.	4.1	3
92	Selected state of the art research in internal medicine, 2017. Internal Medicine Journal, 2018, 48, 619-623.	0.8	0
93	A Phase 3 Study of Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria Naive to Complement Inhibitors: Results of a Subgroup Analysis with Patients Stratified By Baseline Hemolysis Level, Transfusion History, and Demographics. Blood, 2018, 132, 627-627.	1.4	4
94	Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria: Pharmacokinetics and Pharmacodynamics Observed in Two Phase 3 Randomized, Multicenter Studies. Blood, 2018, 132, 626-626.	1.4	7
95	A Prospective Analysis of Breakthrough Hemolysis in 2 Phase 3 Randomized Studies of Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria. Blood, 2018, 132, 2330-2330.	1.4	4
96	Reduced Intensity Conditioned Sibling Transplantation Versus No Transplant in Intermediate or High Risk Acute Myeloid Leukemia: A Prospective Multi-Center Study in Patients 50-70 Years in First Complete Remission and with at Least One Potential Sibling Donor (ClinTrialGov 00342316). Blood, 2018, 132, 205-205.	1.4	2
97	Results from a Phase 3, Multicenter, Non-Inferiority Study of Ravulizumab (ALXN1210) Versus Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with Eculizumab. Blood, 2018, 132, 625-625.	1.4	0
98	A Local Experience of Pregnancy Outcomes in Sickle Cell Disease and Red Cell Exchange. Blood, 2018, 132, 4920-4920.	1.4	1
99	Addressing Ethical and Procedural Principles for Unrelated Allogeneic Hematopoietic Progenitor Cell Donation in a Changing Medical Environment. Biology of Blood and Marrow Transplantation, 2018, 24, 887-894.	2.0	1
100	Panobinostat consolidation in patients with Hodgkin lymphoma at risk for relapse after high dose chemotherapy and autologous stem cell transplant: final results after early trial discontinuation. Leukemia and Lymphoma, 2017, 58, 222-225.	1.3	6
101	Latin America: the next region for haematopoietic transplant progress. Bone Marrow Transplantation, 2017, 52, 671-677.	2.4	39
102	Impact of pre $\alpha$ transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation. Cancer, 2017, 123, 1828-1838.	4.1	73
103	Prognostic Limitations of Donor T Cell Chimerism after Myeloablative Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation, 2017, 23, 840-844.	2.0	10
104	The Journal in 2016. Internal Medicine Journal, 2017, 47, 5-6.	0.8	0
105	Long $\alpha$ term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non $\alpha$ Hodgkin lymphoma. British Journal of Haematology, 2017, 178, 250-256.	2.5	30
106	Pre-transplant ferritin, albumin and haemoglobin are predictive of survival outcome independent of disease risk index following allogeneic stem cell transplantation. Bone Marrow Transplantation, 2017, 52, 870-877.	2.4	21
107	Is a biomarker-based diagnostic strategy for invasive aspergillosis cost effective in high-risk haematology patients?. Medical Mycology, 2017, 55, myw141.	0.7	8
108	Clinical benefit of eculizumab in patients with no transfusion history in the International Paroxysmal Nocturnal Haemoglobinuria Registry. Internal Medicine Journal, 2017, 47, 1026-1034.	0.8	19

#	ARTICLE	IF	CITATIONS
109	Clinical course and disease burden in patients with paroxysmal nocturnal hemoglobinuria by hemolytic status. <i>Blood Cells, Molecules, and Diseases</i> , 2017, 65, 29-34.	1.4	20
110	CD56 <sup>bright</sup> natural killer regulatory cells in filgrastim primed donor blood or marrow products regulate chronic graft- <i>versus</i> -host disease: the Canadian Blood and Marrow Transplant Group randomized O601 study results. <i>Haematologica</i> , 2017, 102, 1936-1946.	3.5	20
111	Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physicians. <i>Molecular Genetics and Metabolism</i> , 2017, 122, 122-129.	1.1	51
112	Economic Challenges in Hematopoietic Cell Transplantation: How Will New and Established Programs Face the Growing Costs?. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1815-1816.	2.0	6
113	Bisphosphonate guidelines for treatment and prevention of myeloma bone disease. <i>Internal Medicine Journal</i> , 2017, 47, 938-951.	0.8	19
114	Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. <i>Blood</i> , 2017, 130, 1156-1164.	1.4	210
115	Graft Transit Time Has No Effect on Outcome of Unrelated Donor Hematopoietic Cell Transplants Performed in Australia and New Zealand: A Study from the Australasian Bone Marrow Transplant Recipient Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 147-152.	2.0	4
116	Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2017, 35, 1678-1685.	1.6	14
117	Nephrotic syndrome as a complication of chronic graft <i>versus</i> host disease after allogeneic haemopoietic stem cell transplantation. <i>Internal Medicine Journal</i> , 2016, 46, 737-741.	0.8	16
118	Safety of Living Donation of Hematopoietic Stem Cells. <i>Transplantation</i> , 2016, 100, 1329-1331.	1.0	7
119	Assessment of human antihuman antibodies to eculizumab after long <i>term</i> treatment in patients with paroxysmal nocturnal hemoglobinuria. <i>American Journal of Hematology</i> , 2016, 91, E16-7.	4.1	13
120	Changing prognosis in paroxysmal nocturnal haemoglobinuria disease subcategories: an analysis of the International <i>PNH</i> Registry. <i>Internal Medicine Journal</i> , 2016, 46, 1044-1053.	0.8	59
121	Could renal impairment be a positive predictor of outcome in autografts for myeloma?. <i>Bone Marrow Transplantation</i> , 2016, 51, 1305-1306.	2.4	0
122	Filgrastim-Stimulated Bone Marrow Compared with Filgrastim-Mobilized Peripheral Blood in Myeloablative Sibling Allografting for Patients with Hematologic Malignancies: A Randomized Canadian Blood and Marrow Transplant Group Study. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1410-1415.	2.0	22
123	All is not lost in accelerated phase/blast crisis and after tyrosine kinase inhibitors fail in chronic myeloid leukaemia: a retrospective study of allogeneic stem cell transplant outcomes in Australia and New Zealand. <i>Bone Marrow Transplantation</i> , 2016, 51, 1400-1403.	2.4	4
124	Uncommon diagnoses do occur. <i>Lancet, The</i> , 2016, 388, 1128.	13.7	0
125	Enzyme replacement therapy with taliglucerase alfa: 36 <i>month</i> safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase. <i>American Journal of Hematology</i> , 2016, 91, 661-665.	4.1	22
126	Effects of intensive induction and consolidation chemotherapy with idarubicin and high dose cytarabine on minimal residual disease levels in newly diagnosed adult precursor-B acute lymphoblastic leukemia. <i>Contemporary Clinical Trials Communications</i> , 2016, 4, 9-13.	1.1	1



#	ARTICLE	IF	CITATIONS
127	Global Use of Peripheral Blood vs Bone Marrow as Source of Stem Cells for Allogeneic Transplantation in Patients With Bone Marrow Failure. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 198.	7.4	18
128	Haploidentical Hematopoietic Stem Cell Transplantation: A Global Overview Comparing Asia, the European Union, and the United States. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 23-26.	2.0	70
129	Reprint of: Haploidentical Hematopoietic Stem Cell Transplantation: A Global Overview Comparing Asia, the European Union, and the United States. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S15-S18.	2.0	47
130	Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey. <i>Bone Marrow Transplantation</i> , 2016, 51, 778-785.	2.4	259
131	Comparing Outcomes with Bone Marrow or Peripheral Blood Stem Cells as Graft Source for Matched Sibling Transplants in Severe Aplastic Anemia across Different Economic Regions. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 932-940.	2.0	43
132	The incidence, mortality and timing of <i>Pneumocystis jiroveci</i> pneumonia after hematopoietic cell transplantation: a CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2016, 51, 573-580.	2.4	68
133	Primary antifungal prophylaxis in adult patients with acute lymphoblastic leukaemia: a multicentre audit. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 497-505.	3.0	30
134	Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 1607-1615.	1.3	17
135	A Review of Hematopoietic Cell Transplantation in Australia and New Zealand, 2005 to 2013. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 284-291.	2.0	28
136	Immediate, Complete, and Sustained Inhibition of C5 with ALXN1210 Reduces Complement-Mediated Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Interim Analysis of a Dose-Escalation Study. <i>Blood</i> , 2016, 128, 2428-2428.	1.4	9
137	A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti-T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2016, 128, 505-505.	1.4	12
138	Increased Idarubicin Dosage during Consolidation Therapy for Adult Acute Myeloid Leukemia Improves Leukemia-Free Survival. <i>Blood</i> , 2016, 128, 338-338.	1.4	0
139	Romiplostim in Thrombocytopenic Patients with Low- or Int-1- Risk MDS Results in Reduced Bleeding without Impacting Leukemic Progression: Final Follow-up Results from a Randomized, Double-Blind, Placebo-Controlled Study. <i>Blood</i> , 2016, 128, 2000-2000.	1.4	2
140	Oral chronic graft-versus-host disease in Australia: clinical features and challenges in management. <i>Internal Medicine Journal</i> , 2015, 45, 702-710.	0.8	11
141	Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort. <i>Internal Medicine Journal</i> , 2015, 45, 1054-1065.	0.8	25
142	Validating the Allogeneic Stem Cell Transplantation Disease Risk Index. <i>Transplantation</i> , 2015, 99, 128-132.	1.0	10
143	Comparison of Outcomes of Allogeneic Transplantation for Chronic Myeloid Leukemia with Cyclophosphamide in Combination with Intravenous Busulfan, Oral Busulfan, or Total Body Irradiation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 552-558.	2.0	12
144	One million haemopoietic stem-cell transplants: a retrospective observational study. <i>Lancet Haematology</i> , 2015, 2, e91-e100.	4.6	329

#	ARTICLE	IF	CITATIONS
145	Older recipient age is paradoxically associated with a lower incidence of chronic GVHD in Thymoglobulin recipients: a retrospective study exploring risk factors for GVHD in allogeneic transplantation with Thymoglobulin GVHD prophylaxis. <i>Bone Marrow Transplantation</i> , 2015, 50, 566-572.	2.4	3
146	Rapid, single-phase extraction of glucosylsphingosine from plasma: A universal screening and monitoring tool. <i>Clinica Chimica Acta</i> , 2015, 450, 6-10.	1.1	25
147	Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial. <i>Lancet Haematology</i> , 2015, 2, e357-e366.	4.6	133
148	Romiplostim in Thrombocytopenic Patients (Pts) with Low-Risk or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) Results in Reduced Bleeding without Impacting Leukemic Progression: Updated Follow-up Results from a Randomized, Double-Blind, Placebo (PBO)-Controlled Study. <i>Blood</i> , 2015, 126, 2863-2863.	1.4	9
149	Long-Term Outcomes, Secondary Malignancies, and Stem Cell Collection Following Bendamustine in Patients with Previously Treated Indolent Non-Hodgkin Lymphoma. <i>Blood</i> , 2015, 126, 3961-3961.	1.4	0
150	Prognostic Markers in Core-Binding Factor Acute Myeloid Leukaemia. <i>Blood</i> , 2015, 126, 2599-2599.	1.4	0
151	Real-World Use of Therapeutic Anticoagulation in Patients with Paroxysmal Nocturnal Hemoglobinuria. Results of a Survey of Physicians in Australia. <i>Blood</i> , 2015, 126, 4537-4537.	1.4	0
152	Patients with Paroxysmal Nocturnal Hemoglobinuria and Hemolysis Demonstrate More Frequent Disease-Related Features Than Those without Hemolysis, but Similar Proportions Experience Thromboembolism. <i>Blood</i> , 2015, 126, 3339-3339.	1.4	0
153	Clinical Benefit of Eculizumab in Patients with No Transfusion History in the International Paroxysmal Nocturnal Hemoglobinuria Registry. <i>Blood</i> , 2015, 126, 3340-3340.	1.4	0
154	Challenges and opportunities for HSCT outcome registries: perspective from international HSCT registries experts. <i>Bone Marrow Transplantation</i> , 2014, 49, 1016-1021.	2.4	25
155	Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry. <i>Haematologica</i> , 2014, 99, 922-929.	3.5	195
156	Ethanol versus heparin locks for the prevention of central venous catheter-associated bloodstream infections: a randomized trial in adult haematology patients with Hickman devices. <i>Journal of Hospital Infection</i> , 2014, 88, 48-51.	2.9	21
157	A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase. <i>Blood Cells, Molecules, and Diseases</i> , 2014, 53, 253-260.	1.4	51
158	Reduced-Intensity Hematopoietic Cell Transplantation for Patients with Primary Myelofibrosis: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 89-97.	2.0	130
159	Autologous Is Superior to Allogeneic Hematopoietic Cell Transplantation for Acute Promyelocytic Leukemia in Second Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1021-1025.	2.0	61
160	Screening with Spirometry Is a Useful Predictor of Later Development of Noninfectious Pulmonary Syndromes in Patients Undergoing Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 781-786.	2.0	25
161	Allotransplantation for Patients Age <math>\geq 40</math> Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 960-968.	2.0	37
162	Allogeneic Stem Cell Transplantation (allo-SCT) for Chronic Myelomonocytic Leukemia â€” a Multicentre Australian Experience: Prognostic Factors for Survival and Relapse. <i>Blood</i> , 2014, 124, 1927-1927.	1.4	2

#	ARTICLE	IF	CITATIONS
163	Causes and Effects of Methotrexate Dose Alterations in Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2014, 124, 2460-2460.	1.4	2
164	Treatment with Romiplostim, a Thrombopoietin-Receptor Agonist, in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (Int-1) Risk Myelodysplastic Syndrome (MDS): Updated Follow-up Results for Acute Myeloid Leukemia (AML) and Survival from a Randomized, Double-Blind, Placebo (PBO)-Controlled Study. <i>Blood</i> , 2014, 124, 3276-3276.	1.4	3
165	Eculizumab Treatment Improves Outcomes of Pregnancy in Patients with Paroxysmal Nocturnal Hemoglobinuria. <i>Blood</i> , 2014, 124, 4393-4393.	1.4	2
166	Intravenous Immunoglobulin Post Allogeneic Stem Cell Transplantation Is Associated with Lower Levels of CMV Reactivation. <i>Blood</i> , 2014, 124, 2482-2482.	1.4	0
167	Choice of Conditioning Regimen Influences Risk of Thymoglobulin Infusion Reactions in Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2014, 124, 5840-5840.	1.4	0
168	Hepatitis <sc>B</sc> serological changes following allogeneic bone marrow transplantation. <i>Transplant Infectious Disease</i> , 2013, 15, 98-103.	1.7	7
169	Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 519-528.	9.1	198
170	Disseminated toxoplasmosis after allogeneic stem cell transplantation in a seronegative recipient. <i>Transplant Infectious Disease</i> , 2013, 15, E14-9.	1.7	18
171	Unrelated Donor Allogeneic Transplantation after Failure of Autologous Transplantation for Acute Myelogenous Leukemia: A Study from the Center for International Blood and Marrow Transplantation Research. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1102-1108.	2.0	17
172	A population-based analysis of the effect of autologous hematopoietic cell transplant in the treatment of multiple myeloma. <i>Leukemia and Lymphoma</i> , 2013, 54, 1671-1676.	1.3	7
173	The Journal in 2012. <i>Internal Medicine Journal</i> , 2013, 43, 1-2.	0.8	4
174	A No-Prophylaxis Platelet-Transfusion Strategy for Hematologic Cancers. <i>New England Journal of Medicine</i> , 2013, 368, 1771-1780.	27.0	384
175	Allogeneic hematopoietic stem cell donationâ€”standardized assessment of donor outcome data: A consensus statement from the Worldwide Network for Blood and Marrow Transplantation (WBMT). <i>Bone Marrow Transplantation</i> , 2013, 48, 220-225.	2.4	46
176	Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study. <i>Haematologica</i> , 2013, 98, 1282-1290.	3.5	110
177	Towards a global system of vigilance and surveillance in unrelated donors of haematopoietic progenitor cells for transplantation. <i>Bone Marrow Transplantation</i> , 2013, 48, 1506-1509.	2.4	11
178	Polymorphism in Human Cytomegalovirus UL40 Impacts on Recognition of Human Leukocyte Antigen-E (HLA-E) by Natural Killer Cells. <i>Journal of Biological Chemistry</i> , 2013, 288, 8679-8690.	3.4	111
179	Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. <i>British Journal of Haematology</i> , 2013, 162, 62-73.	2.5	320
180	Volunteer unrelated donor experience after administration of filgrastim and apheresis for the collection of haemopoietic stem cells: the <sc>A</sc>ustralian perspective. <i>Internal Medicine Journal</i> , 2013, 43, 1183-1190.	0.8	10

#	ARTICLE	IF	CITATIONS
181	Autologous blood cell transplantation versus HLA-identical sibling transplantation for acute myeloid leukemia in first complete remission: a registry study from the Center for International Blood and Marrow Transplantation Research. <i>Haematologica</i> , 2013, 98, 185-192.	3.5	50
182	Global Hematopoietic Stem Cell Transplantation (HSCT) At One Million: An Achievement Of Pioneers and Foreseeable Challenges For The Next Decade. A Report From The Worldwide Network For Blood and Marrow Transplantation (WBMT). <i>Blood</i> , 2013, 122, 2133-2133.	1.4	8
183	A Phase III Randomized, Double Blind, Placebo Controlled Multi-Center Study Of Panobinostat For Maintenance Of Response In Patients With Hodgkin Lymphoma Who Are At Risk For Relapse After High Dose Chemotherapy and Autologous Stem Cell Transplant: Final Results After Early Trial Discontinuation. <i>Blood</i> , 2013, 122, 4648-4648.	1.4	10
184	A Canadian Blood and Marrow Transplant Group (CBMTG) Randomised Trial Comparing G-CSF Mobilized Peripheral Blood Versus G-CSF Stimulated Bone Marrow In Recipients Of Sibling Allografts For Hematologic Malignancies. <i>Blood</i> , 2013, 122, 709-709.	1.4	3
185	Single-Centre Validation Of a Disease Risk Index For Estimating Survival and Relapse In Allogeneic Hematopoietic Stem Cell Transplant Recipients: Sample Size, Adequate Follow-Up, and Use Of Local Data Are Vital Considerations. <i>Blood</i> , 2013, 122, 2143-2143.	1.4	0
186	Palifermin for the reduction of acute GVHD: a randomized, double-blind, placebo-controlled trial. <i>Bone Marrow Transplantation</i> , 2012, 47, 1350-1355.	2.4	20
187	Constrictive pericarditis and primary effusion lymphoma following allogeneic BMT for CML. <i>Bone Marrow Transplantation</i> , 2012, 47, 1250-1251.	2.4	4
188	All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). <i>Blood</i> , 2012, 120, 1570-1580.	1.4	268
189	Allogeneic Hematopoietic Cell Transplantation for Chronic Myelofibrosis in Australia and New Zealand: Older Recipients Receiving Myeloablative Conditioning at Increased Mortality Risk. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 302-308.	2.0	25
190	The Effect of Folinic Acid on Methylenetetrahydrofolate Reductase Polymorphisms in Methotrexate-Treated Allogeneic Hematopoietic Stem Cell Transplants. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 722-730.	2.0	9
191	Recommended Screening and Preventive Practices for Long-Term Survivors after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 348-371.	2.0	324
192	Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2012, 47, 810-816.	2.4	83
193	The Journal in 2011. <i>Internal Medicine Journal</i> , 2012, 42, 1-2.	0.8	3
194	The prevalent predicament of relapsed acute myeloid leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 43-8.	2.5	26
195	Long-Term Safety of Sustained Eculizumab Treatment in Patients with Paroxysmal Nocturnal Hemoglobinuria. <i>Blood</i> , 2012, 120, 1260-1260.	1.4	1
196	Global Trends in Hematopoietic Cell Transplantation.. <i>Blood</i> , 2012, 120, 3143-3143.	1.4	2
197	Treatment with the Thrombopoietin (TPO)-Receptor Agonist Romiplostim in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS): Follow-up AML and Survival Results of a Randomized, Double-Blind, Placebo (PBO)-Controlled Study. <i>Blood</i> , 2012, 120, 421-421.	1.4	9
198	Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2012, 34, 109-133.	0.7	207

#	ARTICLE	IF	CITATIONS
199	Clinical roundtable monograph: Paroxysmal nocturnal hemoglobinuria: a case-based discussion. <i>Clinical Advances in Hematology and Oncology</i> , 2012, 10, 1-16.	0.3	1
200	Enzyme replacement therapy "drug holiday": Results from an unexpected shortage of an orphan drug supply in Australia. <i>Blood Cells, Molecules, and Diseases</i> , 2011, 46, 107-110.	1.4	39
201	Increased activity and improved outcome in unrelated donor haemopoietic cell transplants for acute myeloid leukaemia in Australia, 1992-2005. <i>Internal Medicine Journal</i> , 2011, 41, 27-34.	0.8	6
202	Introduction to the Australian consensus guidelines for the management of neutropenic fever in adult cancer patients, 2010/2011. <i>Internal Medicine Journal</i> , 2011, 41, 75-81.	0.8	27
203	An Australian survey of clinical practices in management of neutropenic fever in adult cancer patients 2009. <i>Internal Medicine Journal</i> , 2011, 41, 110-120.	0.8	22
204	The Journal in 2010. <i>Internal Medicine Journal</i> , 2011, 41, 1-2.	0.8	0
205	How we mobilize haemopoietic stem cells. <i>Internal Medicine Journal</i> , 2011, 41, 588-594.	0.8	8
206	MLL-aberrant leukemia: complete cytogenetic remission following treatment with a histone deacetylase inhibitor (HDACi). <i>Annals of Hematology</i> , 2011, 90, 847-849.	1.8	13
207	Allogeneic hematopoietic cell transplant for multiple myeloma using reduced intensity conditioning therapy, 1998-2006: factors associated with improved survival outcome. <i>Leukemia and Lymphoma</i> , 2011, 52, 1727-1735.	1.3	9
208	Flow-cytometric minimal residual disease monitoring for chronic lymphocytic leukemia in the post-allogeneic transplant period. <i>Leukemia and Lymphoma</i> , 2011, 52, 2185-2187.	1.3	3
209	Design issues in a randomized controlled trial of a pre-emptive versus empiric antifungal strategy for invasive aspergillosis in patients with high-risk hematologic malignancies. <i>Leukemia and Lymphoma</i> , 2011, 52, 179-193.	1.3	16
210	A cost analysis of febrile neutropenia management in Australia: ambulatory v. in-hospital treatment. <i>Australian Health Review</i> , 2011, 35, 491.	1.1	20
211	Treatment with the Thrombopoietin (TPO)-Receptor Agonist Romiplostim in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (Int-1) Risk Myelodysplastic Syndrome (MDS): Results of a Randomized, Double-Blind, Placebo(PBO)-Controlled Study. <i>Blood</i> , 2011, 118, 117-117.	1.4	12
212	Clinical Characteristics of Classic Paroxysmal Nocturnal Hemoglobinuria (PNH) in Pediatric Patients: A Comparison with Classic PNH in Adults. An International PNH Registry Study. <i>Blood</i> , 2011, 118, 2102-2102.	1.4	2
213	Global Use and Trends in Hematopoietic Stem Cell Transplantation Analyzed by the Worldwide Network of Blood and Marrow Transplantation WBMT: A Targeted Approach for a Widening Gap. <i>Blood</i> , 2011, 118, 1016-1016.	1.4	1
214	Haemopoietic Improvement Following Iron Chelation for Transfusional Haemosiderosis in Patients with Haematopoietic Neoplasia and Aplastic Anaemia: An Observational Study. <i>Blood</i> , 2011, 118, 5050-5050.	1.4	4
215	The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. <i>Blood</i> , 2010, 116, 366-374.	1.4	178
216	The substrate is down: is the IV out?. <i>Blood</i> , 2010, 116, 860-861.	1.4	1

#	ARTICLE	IF	CITATIONS
217	Mentoring in the management of hematological malignancies. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2010, 6, 28-34.	1.1	4
218	Incidence and reasons for late failure after allogeneic haematopoietic cell transplantation following BuCy2 in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2010, 148, 623-626.	2.5	4
219	Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy. <i>British Journal of Haematology</i> , 2010, 150, 39-45.	2.5	72
220	The Journal in 2009. <i>Internal Medicine Journal</i> , 2010, 40, 1-2.	0.8	0
221	Virtual everything. <i>Internal Medicine Journal</i> , 2010, 40, 473-473.	0.8	0
222	Durable resolution of recurrent microvascular small bowel ischaemia and severe abdominal pain by eculizumab in paroxysmal nocturnal haemoglobinuria. <i>Internal Medicine Journal</i> , 2010, 40, 794-795.	0.8	4
223	Hematopoietic Stem Cell Transplantation & subtitle A Global Perspective & subtitle. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 1617.	7.4	556
224	Etoposide induces more severe mucositis than CY when added to TBI as conditioning in allograft recipients receiving CsA and MTX. <i>Bone Marrow Transplantation</i> , 2010, 45, 1457-1462.	2.4	10
225	Allogeneic Hematopoietic Cell Transplant for Prolymphocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 543-547.	2.0	37
226	Evaluation of Paroxysmal Nocturnal Hemoglobinuria Disease Burden: The Patient's Perspective. A Report From the International PNH Registry. <i>Blood</i> , 2010, 116, 1525-1525.	1.4	5
227	Use of Blood Transfusions In Paroxysmal Nocturnal Hemoglobinuria Patients with and without Aplastic Anemia Enrolled In the Global PNH Registry. <i>Blood</i> , 2010, 116, 2241-2241.	1.4	6
228	Long Term Safety and Efficacy of Sustained Eculizumab Treatment In Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). <i>Blood</i> , 2010, 116, 4237-4237.	1.4	4
229	The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. <i>Leukemia</i> , 2009, 23, 2034-2041.	7.2	91
230	Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment. <i>Internal Medicine Journal</i> , 2009, 39, 304-316.	0.8	44
231	The Journal in 2008. <i>Internal Medicine Journal</i> , 2009, 39, 1-4.	0.8	6
232	Late Mortality and Relapse following BuCy2 and HLA-Identical Sibling Marrow Transplantation for Chronic Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 851-855.	2.0	13
233	Relative Survival of Long-Term Hematopoietic Cell Transplant Recipients Approaches General Population Rates. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1323-1330.	2.0	27
234	Sibling versus Unrelated Donor Allogeneic Hematopoietic Cell Transplantation for Chronic Myelogenous Leukemia: Refined HLA Matching Reveals More Graft-versus-Host Disease but not Less Relapse. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1475-1478.	2.0	39



#	ARTICLE	IF	CITATIONS
235	The Tolerability of Combination Therapy with Thalidomide and 5-Azacididine in Patients with Advanced Myelodysplastic Syndromes (MDS).. <i>Blood</i> , 2009, 114, 1749-1749.	1.4	1
236	Hematopoietic Stem Cell Transplantation: a Global Perspective From the Worldwide Network of Blood and Marrow Transplantation.. <i>Blood</i> , 2009, 114, 809-809.	1.4	3
237	A Global Registry of Patients with Paroxysmal Nocturnal Hemoglobinuria.. <i>Blood</i> , 2009, 114, 3007-3007.	1.4	0
238	Cyclosporin, methotrexate and prednisolone for graft-versus-host disease prophylaxis in allogeneic peripheral blood progenitor cell transplants. <i>Bone Marrow Transplantation</i> , 2008, 41, 651-658.	2.4	17
239	The Journal in 2007. <i>Internal Medicine Journal</i> , 2008, 38, 1-2.	0.8	22
240	Harvesting haemopoietic stem cells for future use: rainy days, real or imagined?. <i>Internal Medicine Journal</i> , 2008, 38, 227-228.	0.8	1
241	Antifungal prophylaxis in adult stem cell transplantation and haematological malignancy. <i>Internal Medicine Journal</i> , 2008, 38, 468-476.	0.8	31
242	Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. <i>British Journal of Haematology</i> , 2008, 142, 263-272.	2.5	50
243	A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial. <i>BMC Cancer</i> , 2008, 8, 195.	2.6	46
244	Long-term toxicity of allogeneic stem cell transplantation in fludarabine-refractory chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2008, 49, 896-901.	1.3	3
245	Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. <i>Blood</i> , 2008, 112, 3500-3507.	1.4	127
246	Mannose-binding lectin status is associated with risk of major infection following myeloablative sibling allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2008, 112, 2120-2128.	1.4	45
247	Late Mortality and Relapse Following HLA-Identical Sibling Donor Marrow Transplantation for Chronic Myeloid Leukemia.. <i>Blood</i> , 2008, 112, 3264-3264.	1.4	40
248	Complete Remission on 18F-FDG-PET Prior to Autologous Stem Cell Transplantation Predicts Superior Event Free Survival of Patients with Relapsed or Refractory Hodgkin Lymphoma.. <i>Blood</i> , 2008, 112, 2188-2188.	1.4	0
249	Incidence of Late Failure Following Myeloablative Conditioning with BuCy2 and Matched Sibling Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia.. <i>Blood</i> , 2008, 112, 2172-2172.	1.4	0
250	A Prospective Multicenter Trial of Peripheral Blood Stem Cell Sibling Allografts for Acute Myeloid Leukemia in First Complete Remission Using Fludarabine-Cyclophosphamide Reduced Intensity Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 560-567.	2.0	24
251	Equivalent Survival for Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 601-607.	2.0	86
252	Hematopoietic Stem Cell Transplantation in Australia and New Zealand, 1992-2004. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 905-912.	2.0	29

#	ARTICLE	IF	CITATIONS
253	Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. <i>Blood</i> , 2007, 110, 4123-4128.	1.4	481
254	A randomized comparison of empiric or pre-emptive antibiotic therapy after hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2007, 40, 157-163.	2.4	29
255	Caspofungin as salvage monotherapy for invasive aspergillosis in patients with haematological malignancies or following allogeneic stem cell transplantation: efficacy and concomitant cyclosporin A. <i>Mycoses</i> , 2007, 50, 24-37.	4.0	24
256	Focal lesions on magnetic resonance imaging in aplastic anaemia: Multiple metastases or haemopoietic marrow. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2007, 51, B110-4.	0.6	5
257	Breakthrough <i>Scedosporium prolificans</i> infection while receiving voriconazole prophylaxis in an allogeneic stem cell transplant recipient. <i>Transplant Infectious Disease</i> , 2007, 9, 241-243.	1.7	43
258	The Journal in 2006. <i>Internal Medicine Journal</i> , 2007, 37, 1-2.	0.8	0
259	Enzyme replacement therapy for Gaucher disease in Australia. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2007, 91, 153-153.	1.5	0
260	Post-Consolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in AML: Long Term Follow-Up of Leukemia-Free Survival and Overall Survival.. <i>Blood</i> , 2007, 110, 1846-1846.	1.4	4
261	Sustained Improvements in Transfusion Requirements, Fatigue and Thrombosis with Eculizumab Treatment in Paroxysmal Nocturnal Hemoglobinuria.. <i>Blood</i> , 2007, 110, 3672-3672.	1.4	3
262	Impact on Quality of Life of Postconsolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in Acute Myelogenous Leukemia.. <i>Blood</i> , 2007, 110, 4381-4381.	1.4	1
263	Improved Relapse Free Survival Is Predicted by a Negative Pre-Transplant FDG-PET Scan Following Salvage Chemotherapy for Relapsed Diffuse Large B Cell Lymphoma (DLBCL) Treated with Autologous Stem Cell Transplantation.. <i>Blood</i> , 2007, 110, 5115-5115.	1.4	0
264	Risk Factors for Blood Product Usage Following Sibling Allogeneic Haemopoietic Stem Cell Transplantation (allo-HCT).. <i>Blood</i> , 2007, 110, 2909-2909.	1.4	0
265	The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. <i>New England Journal of Medicine</i> , 2006, 355, 1233-1243.	27.0	1,060
266	Allogeneic Stem Cell Transplantation with Peripheral Blood Stem Cells Mobilized by Pegylated G-CSF. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 603-607.	2.0	40
267	Genetic heterogeneity of granulocytes for the JAK2 V617F mutation in essential thrombocythaemia: implications for mutation detection in peripheral blood. <i>Pathology</i> , 2006, 38, 336-342.	0.6	14
268	More on Myb in myelofibrosis: molecular analyses of MYB and EP300 in 55 patients with myeloproliferative disorders. <i>Blood</i> , 2006, 107, 1733-1735.	1.4	10
269	Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. <i>Blood</i> , 2006, 108, 88-96.	1.4	226
270	The Journal in 2005. <i>Internal Medicine Journal</i> , 2006, 36, 1-2.	0.8	6

#	ARTICLE	IF	CITATIONS
271	Democracy or dictatorship at the bedside?. Internal Medicine Journal, 2006, 36, 275-275.	0.8	1
272	Zoledronic acid prevents bone loss after allogeneic haemopoietic stem cell transplantation. Internal Medicine Journal, 2006, 36, 600-603.	0.8	46
273	Relapsed blastic natural killer cell leukaemia with splenic rupture. British Journal of Haematology, 2006, 135, 2-2.	2.5	2
274	Donor methylenetetrahydrofolate reductase genotype is associated with graft-versus-host disease in hematopoietic stem cell transplant patients treated with methotrexate. Bone Marrow Transplantation, 2006, 37, 773-779.	2.4	33
275	Reduced-intensity allogeneic haemopoietic stem cell transplantation induces durable responses in patients with chronic B-lymphoproliferative disorders. Bone Marrow Transplantation, 2006, 37, 923-928.	2.4	20
276	Female genital tract graft-versus-host disease: incidence, risk factors and recommendations for management. Bone Marrow Transplantation, 2006, 38, 567-572.	2.4	96
277	Long-term survival data from a phase 3 study of Filgrastim as an adjunct to chemotherapy in adults with de novo acute myeloid leukemia. Leukemia, 2006, 20, 404-409.	7.2	28
278	The immunophenotype of acute myeloid leukemia: is there a relationship with prognosis?. Blood Reviews, 2006, 20, 71-82.	5.7	48
279	The hyper-CVAD rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. Annals of Hematology, 2006, 86, 101-105.	1.8	63
280	Pamidronate Reduces Bone Loss after Allogeneic Stem Cell Transplantation. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 3835-3843.	3.6	70
281	A Randomized, Open-Label, Multicenter Comparative Study of the Efficacy and Safety of Piperacillin-Tazobactam and Cefepime for the Empirical Treatment of Febrile Neutropenic Episodes in Patients with Hematologic Malignancies. Clinical Infectious Diseases, 2006, 43, 447-459.	5.8	106
282	Treatment with the Terminal Complement Inhibitor Eculizumab Improves Anemia in Patients with Paroxysmal Nocturnal Hemoglobinuria: Phase III Triumph Study Results.. Blood, 2006, 108, 124-124.	1.4	13
283	Long Term Follow-Up of Patients with Chronic Myeloid Leukemia Receiving BuCy2 as Preparation for Allotransplantation.. Blood, 2006, 108, 3364-3364.	1.4	1
284	Long-Term Follow-Up of Treatment for Acute Myeloid Leukemia with Allogeneic Hematopoietic Cell Transplantation Using BuCy2 as Preparation.. Blood, 2006, 108, 3370-3370.	1.4	0
285	Mannose-Binding Lectin Status Is Associated with Risk of Major Infection Following Myeloablative Sibling Allogeneic Hematopoietic Stem Cell Transplantation.. Blood, 2006, 108, 2928-2928.	1.4	1
286	Extended TNF Genotyping Identifies TNF -857T as a Risk Factor for Acute Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation.. Blood, 2006, 108, 39-39.	1.4	0
287	A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine. Blood, 2005, 105, 481-488.	1.4	91
288	Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation. Journal of Thrombosis and Haemostasis, 2005, 3, 1935-1944.	3.8	125

#	ARTICLE	IF	CITATIONS
289	Haemopoietic stem cell transplantation in Australia and New Zealand, 1992-2001: progress report from the Australasian Bone Marrow Transplant Recipient Registry. <i>Internal Medicine Journal</i> , 2005, 35, 18-27.	0.8	17
290	The Journal in 2004. <i>Internal Medicine Journal</i> , 2005, 35, 1-2.	0.8	2
291	Enzyme replacement therapy for Gaucher disease in Australia. <i>Internal Medicine Journal</i> , 2005, 35, 156-161.	0.8	8
292	Optimal scheduling to reduce morbidity of involved field radiotherapy with transplantation for lymphomas: A Prospective Australasian Leukaemia and Lymphoma Group Study. <i>Bone Marrow Transplantation</i> , 2005, 35, 291-298.	2.4	13
293	Sustained remission, possibly cure, of seronegative arthritis after high-dose chemotherapy and syngeneic hematopoietic stem cell transplantation. <i>Arthritis and Rheumatism</i> , 2005, 52, 3322-3322.	6.7	12
294	Allogeneic Stem Cell Transplantation with Peripheral Blood Stem Cells Mobilized by Pegylated-G-CSF.. <i>Blood</i> , 2005, 106, 1970-1970.	1.4	0
295	Cladribine followed by autologous stem-cell transplantation in progressive multiple sclerosis. <i>Internal Medicine Journal</i> , 2004, 34, 66-69.	0.8	1
296	Guidelines for the use of antifungal agents in the treatment of invasive <i>Candida</i> and mould infections. <i>Internal Medicine Journal</i> , 2004, 34, 192-200.	0.8	46
297	Oral versus intravenous ganciclovir for the prophylaxis of cytomegalovirus disease after allogeneic bone marrow transplantation. <i>Internal Medicine Journal</i> , 2004, 34, 98-101.	0.8	10
298	Staged autologous peripheral blood progenitor cell transplantation for Ewing sarcoma and rhabdomyosarcoma. <i>Internal Medicine Journal</i> , 2004, 34, 431-434.	0.8	7
299	Cerebral nocardiosis after allogeneic bone marrow transplantation. <i>Internal Medicine Journal</i> , 2004, 34, 698-699.	0.8	11
300	Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2004, 34, 115-121.	2.4	75
301	A pilot study of targeted itraconazole prophylaxis in patients with graft-versus-host disease at high risk of invasive mould infections following allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2004, 34, 447-453.	2.4	20
302	Non-HLA immunogenetic polymorphisms and the risk of complications after allogeneic hemopoietic stem-cell transplantation. <i>Transplantation</i> , 2004, 77, 587-596.	1.0	76
303	When to transplant in myelodysplasia? Markov helps. <i>Blood</i> , 2004, 104, 304-305.	1.4	3
304	Activated Recombinant Factor VII (rFVIIa/NovoSeven <sup>®</sup> ) in the Treatment of Bleeding Complications Following Hematopoietic Stem Cell Transplantation (HSCT).. <i>Blood</i> , 2004, 104, 1135-1135.	1.4	1
305	Pamidronate Therapy for One Year after Allogeneic Bone Marrow Transplantation (AlloBMT) Reduces Bone Loss from the Lumbar Spine, Femoral Neck and Total Hip.. <i>Blood</i> , 2004, 104, 2253-2253.	1.4	6
306	Improved Leukemia-Free Survival after Post-Consolidation Treatment with Histamine Dihydrochloride and Interleukin-2 in AML: A Randomized Phase III Trial.. <i>Blood</i> , 2004, 104, 261-261.	1.4	5

#	ARTICLE	IF	CITATIONS
307	A Multicentre, Double-Blind, Randomized, Phase 2 Trial Comparing Pegfilgrastim with Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML).. <i>Blood</i> , 2004, 104, 866-866.	1.4	4
308	A Matched Pair Retrospective Comparison of Adult Unrelated and Sibling Donor Allogeneic Transplantation for AML.. <i>Blood</i> , 2004, 104, 5173-5173.	1.4	0
309	Tissue Iron Overload Is Common Post Transplantation (Allo BMT) and Is Associated with Red Cell Transfusion Load and HFE Genotype.. <i>Blood</i> , 2004, 104, 2262-2262.	1.4	0
310	Conditioning with Fludarabine (Flu)-Alkylator Is More Effective Cyto-reduction Than Cyclophosphamide-Total Body Irradiation (Cy/TBI) for Refractory, Progressive Chronic Lymphatic Leukemia (CLL).. <i>Blood</i> , 2004, 104, 5045-5045.	1.4	0
311	Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia? a randomized, placebo-controlled, double-blind safety and efficacy study. <i>Annals of Hematology</i> , 2003, 82, 677-683.	1.8	25
312	Morphological effects of imatinib mesylate (STI571) on the bone marrow and blood of patients with Philadelphia chromosome (Ph) positive chronic myeloid leukaemia. <i>International Journal of Laboratory Hematology</i> , 2003, 25, 119-125.	0.2	7
313	The incidence, pathogenesis and natural history of steatorrhoea after bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 2003, 31, 701-703.	2.4	18
314	Differences between graft product and donor side effects following bone marrow or stem cell donation. <i>Bone Marrow Transplantation</i> , 2003, 32, 873-880.	2.4	76
315	Prolonged molecular remission after arsenic trioxide and all-trans retinoic acid for acute promyelocytic leukemia relapsed after allogeneic stem cell transplantation. <i>Leukemia</i> , 2003, 17, 1916-1917.	7.2	11
316	Graft-versus-host disease, donor chimerism, and organ toxicity in stem cell transplantation after conditioning with fludarabine and melphalan. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 435-442.	2.0	22
317	Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. <i>Blood</i> , 2003, 102, 276-283.	1.4	707
318	Sequential Transformation of t(8;13)-Related Disease. <i>Acta Haematologica</i> , 2002, 107, 95-97.	1.4	17
319	Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantation. <i>Blood</i> , 2002, 99, 3524-3529.	1.4	192
320	Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. <i>Blood</i> , 2002, 100, 761-767.	1.4	258
321	BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration. <i>Cancer Genetics and Cytogenetics</i> , 2002, 139, 30-33.	1.0	69
322	A pilot randomized trial comparing CD34-selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2002, 46, 2301-2309.	6.7	153
323	Cisplatin, fludarabine, and cytarabine. <i>Cancer</i> , 2002, 94, 585-593.	4.1	30
324	A phase I dose-escalation study of etoposide continuous infusion added to busulphan/cyclophosphamide as conditioning prior to autologous or allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2002, 30, 645-650.	2.4	8

#	ARTICLE	IF	CITATIONS
325	The Adaptation of Patients During the Hospitalization Period of Bone Marrow Transplantation. <i>Journal of Clinical Psychology in Medical Settings</i> , 2002, 9, 167-175.	1.4	14
326	Fludarabine and mitoxantrone: Effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders. <i>Annals of Oncology</i> , 2001, 12, 1455-1460.	1.2	28
327	Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. <i>Blood</i> , 2001, 98, 1732-1738.	1.4	228
328	Patterns of failure with increasing intensification of induction chemotherapy for acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2001, 113, 727-736.	2.5	23
329	Chemotherapy and granulocyte colony stimulating factor-mobilized blood cell infusion followed by interferon- $\alpha$ for relapsed malignancy after allogeneic bone marrow transplantation. <i>Internal Medicine Journal</i> , 2001, 31, 15-22.	0.8	24
330	Small molecule: large hopes. <i>Internal Medicine Journal</i> , 2001, 31, 382-383.	0.8	0
331	Allogeneic haemopoietic cell transplants in Australia, 1996 - A multi-centre retrospective comparison of the use of peripheral blood stem cells with bone marrow. <i>Bone Marrow Transplantation</i> , 2001, 28, 21-27.	2.4	11
332	Acute left ventricular failure following melphalan and fludarabine conditioning. <i>Bone Marrow Transplantation</i> , 2001, 28, 101-103.	2.4	58
333	Abnormal cervical cytology in bone marrow transplant recipients. <i>Bone Marrow Transplantation</i> , 2001, 28, 393-397.	2.4	51
334	Atypical retinal microvasculopathy after bone marrow transplantation. <i>Clinical and Experimental Ophthalmology</i> , 2001, 29, 225-229.	2.6	15
335	Prolonged Disease-Free Survival after Autografting for Chemosensitive Non-Bulky Low Grade Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 2000, 39, 283-290.	1.3	4
336	Multicycle High-Dose Chemotherapy and Filgrastim-Mobilized Peripheral-Blood Progenitor Cells in Women With High-Risk Stage II or III Breast Cancer: Five-Year Follow-Up. <i>Journal of Clinical Oncology</i> , 1999, 17, 82-82.	1.6	21
337	Bone marrow transplants for paroxysmal nocturnal haemoglobinuria. <i>British Journal of Haematology</i> , 1999, 104, 392-396.	2.5	110
338	Factors affecting the outcome of allogeneic bone marrow transplantation for adult patients with refractory or relapsed acute leukaemia. <i>British Journal of Haematology</i> , 1999, 107, 409-418.	2.5	59
339	The addition of allogeneic peripheral blood-derived progenitor cells to bone marrow for transplantation: results of a randomised clinical trial. <i>Australian and New Zealand Journal of Medicine</i> , 1999, 29, 487-493.	0.5	7
340	Mechanisms of Bone Loss Following Allogeneic and Autologous Hemopoietic Stem Cell Transplantation. <i>Journal of Bone and Mineral Research</i> , 1999, 14, 342-350.	2.8	156
341	High-Dose Chemotherapy and Syngeneic Hemopoietic Stem-Cell Transplantation for Severe, Seronegative Rheumatoid Arthritis. <i>Annals of Internal Medicine</i> , 1999, 131, 507.	3.9	42
342	HLA-identical sibling peripheral blood cell transplants. The Australian experience and preliminary results of a randomised study. <i>Bone Marrow Transplantation</i> , 1998, 21 Suppl 3, S57-8.	2.4	0



#	ARTICLE	IF	CITATIONS
343	High Dose Cytosine Arabinoside is a Major Risk Factor for the Development of Hepatosplenic Candidiasis in Patients with Leukemia. <i>Leukemia and Lymphoma</i> , 1997, 27, 469-474.	1.3	14
344	Variability in Determination of Body Weight Used for Dosing Busulphan and Cyclophosphamide in Adult Patients: Results of an International Survey. <i>Leukemia and Lymphoma</i> , 1997, 25, 487-491.	1.3	20
345	Mobilization of predominantly Philadelphia chromosome-negative blood progenitors using cyclophosphamide and rHUG-CSF in early chronic-phase chronic myeloid leukaemia: correlation with Sokal prognostic index and haematological control. <i>British Journal of Haematology</i> , 1997, 96, 635-640.	2.5	13
346	Alloresponses to HLA-DP Detected in the Primary MLR: Correlation with a Single Amino Acid Difference. <i>Human Immunology</i> , 1997, 55, 163-169.	2.4	26
347	Perturbation in the ability of bone marrow stroma from patients with acute myeloid leukemia but not chronic myeloid leukemia to support normal early hematopoietic progenitor cells. <i>Leukemia Research</i> , 1997, 21, 29-36.	0.8	20
348	Autologous hemopoietic stem cell transplantation. A possible cure for rheumatoid arthritis?. <i>Arthritis and Rheumatism</i> , 1997, 40, 1005-1011.	6.7	35
349	Allogeneic peripheral blood progenitor cell transplantation—the Australian experience. <i>Bone Marrow Transplantation</i> , 1996, 17 Suppl 2, S51-3.	2.4	0
350	Application of interphase cytogenetics to monitor bone marrow transplants. <i>American Journal of Hematology</i> , 1995, 49, 15-20.	4.1	4
351	Combined Chemotherapy and Granulocyte Colony-Stimulating Factor (G-CSF) Mobilise Large Numbers of Peripheral Blood Progenitor Cells in Pretreated Patients. <i>Leukemia and Lymphoma</i> , 1994, 15, 91-97.	1.3	7
352	The Influence of Induction Chemotherapy Dose and Dose Intensity on the Duration of Remission in Acute Myeloid Leukemia. <i>Leukemia and Lymphoma</i> , 1994, 15, 79-84.	1.3	13
353	Current thinking in the management of leukaemia. <i>Australian Family Physician</i> , 1994, 23, 1500-5.	0.5	0
354	Donor leucocyte infusions after chemotherapy for patients relapsing with acute leukaemia following allogeneic BMT. <i>Bone Marrow Transplantation</i> , 1993, 11, 109-11.	2.4	47
355	Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. <i>Lancet, The</i> , 1992, 339, 640-644.	13.7	872
356	G-CSF-mobilized peripheral and autologous bone marrow infusion following high dose chemotherapy. <i>International Journal of Cell Cloning</i> , 1992, 10, 71-73.	1.6	6
357	Post-remission therapy for acute myeloid leukaemia with blood-derived stem cell transplantation. Results of a collaborative phase II trial. <i>International Journal of Cell Cloning</i> , 1992, 10, 114-116.	1.6	13
358	Studies of oral neutrophil levels in patients receiving G-CSF after autologous marrow transplantation. <i>British Journal of Haematology</i> , 1992, 82, 589-595.	2.5	69
359	Chronic myeloid leukemia treated by allogeneic bone marrow transplantation. <i>Transplantation Proceedings</i> , 1992, 24, 181-2.	0.6	0
360	Chronic myeloid leukaemia treated by allogeneic bone marrow transplantation from histocompatible sibling donors — an invariably fatal malignancy rendered highly curable. <i>Australian and New Zealand Journal of Medicine</i> , 1991, 21, 408-413.	0.5	1

#	ARTICLE	IF	CITATIONS
361	Treatment of acute promyelocytic leukaemia relapsing after allogeneic bone marrow transplantation with all-trans-retinoic acid: suppression of the leukaemic clone. <i>British Journal of Haematology</i> , 1991, 79, 331-334.	2.5	7
362	Combination prophylactic immunosuppression in bone marrow transplantation. <i>Transplantation Proceedings</i> , 1989, 21, 3011-2.	0.6	2
363	RFPLY. <i>Australian and New Zealand Journal of Medicine</i> , 1983, 13, 643-643.	0.5	0
364	Allogeneic hematopoietic cell transplant for multiple myeloma using reduced intensity conditioning therapy, 1998-2006: factors associated with improved survival outcome. <i>Leukemia and Lymphoma</i> , 0, , 1-9.	1.3	0
365	Predictors and Outcomes of Dose Reduction of Methotrexate and Cyclosporin <scp>Graft-versus-Host-Disease</scp> Prophylaxis Following Allogeneic Haematopoietic Cell Transplantation. <i>Internal Medicine Journal</i> , 0, , .	0.8	0
366	Fat fraction quantification of bone marrow in the lumbar spine using the LiverLab assessment tool in healthy adult volunteers and patients with Gaucher Disease. <i>Internal Medicine Journal</i> , 0, , .	0.8	1